| Document |
Document Title |
|
WO/2004/002530A1 |
A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, chro...
|
|
WO/2004/002409A2 |
The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or re...
|
|
WO/2004/002965A1 |
The invention relates to novel arylcarboxamides and heteroarylcarboxamides of general formula (I), to the production thereof, and to the use of the same as pharmaceuticals, especially for treating tumours.
|
|
WO/2004/000817A2 |
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein at least one of R?1¿ and R?2¿ is a group of the formula (II), wherein R?7¿, R?8¿, R?10¿ and R?11¿ are each independently hydrogen; hydroxy; (C¿1?-C¿6...
|
|
WO/2004/001058A2 |
Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: 1) a selectable marker un...
|
|
WO/2003/101933A1 |
Novel solid supported intermediate products of the general formula I coupled to a solid polymeric support through one or both of the R&supl groups or through the R4 group which are suitable for synthesis of heterocyclic compounds are dis...
|
|
WO/2003/099221A2 |
The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the diseas...
|
|
WO/2003/099192A2 |
The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them.
|
|
WO/2003/099776A1 |
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...
|
|
WO/2003/096984A2 |
Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by a...
|
|
WO/2003/097616A1 |
The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs esters and metabolites thereof. It further relates to their use as broadspectrum HIV protease inhibitors, p...
|
|
WO/2003/097047A1 |
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I);or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of s...
|
|
WO/2003/096979A2 |
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
|
|
WO/2003/092682A1 |
The present invention is directed to a method of treating overweight and/or obesity and eating disorders such as binge-eating disorders, bulimia nervosa andanorexia nervosa. The method comprises administering to a subject a pharmaceutica...
|
|
WO/2003/093250A2 |
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...
|
|
WO/2003/090539A1 |
The invention relates to 3-heteroaryl substituted isoxazolines of formula (I), or to their salts that can be used for agricultural purposes. In said formula, the variables are defined as follows: X represents a substituted 5-membered het...
|
|
WO/2003/089404A1 |
The present invention relates to naphthylamide compounds and their ability to act as potassium channel openers.
|
|
WO/2003/088959A2 |
A method of treating, preventing, or inhibiting PD, in a subject in need of such treatment, inhibition or prevention. The method comprises treating the subject with one or more cyclooxygenase-2 selective inhibitor(s), ester(s), salt(s) o...
|
|
WO/2003/086287A2 |
Compounds useful for inducing apoptosis in proliferate cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer...
|
|
WO/2003/086391A1 |
This invention relates to a new use of a compound of the following formula (I) or (II) for the manufacture of a medicament for preventing and/or treating chronic rejection in a transplanted organ or tissue.
|
|
WO/2003/087062A2 |
The present invention describes novel compounds of formula (I) having antiinflammatory activity, process for their preparation and pharmaceutical composition containing them.
|
|
WO/2003/087084A1 |
The invention relates to 3-aminophenol derivatives of formula (I) or to their physiologically compatible, water-soluble salts, and to dyes that contain these compounds while based on a developing agent/coupling agent combination.
|
|
WO/2003/087037A1 |
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...
|
|
WO/2003/084915A1 |
This invention relates to novel compounds according to the general formula : which are thyroid receptor ligands, preferably antagonists, partial antagonists or partial agonists and to methods for using such compounds in the treatment of ...
|
|
WO/2003/085005A1 |
A photopolymerizable composition comprising a metal complex of a squarylium compound, a radical generating agent and a compound containing at least one ethylenically unsaturated double bond. The photopolymerizable composition exhibits en...
|
|
WO/2003/084916A2 |
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods o...
|
|
WO/2003/084927A1 |
Haloalkenes represented by the general formula (I) which are useful as pest controllers: (I) wherein X1 and X2 are each halogeno; Y is hydrogen or halogeno; n is 0 to 5; and Q is (1) a heterocyclic group selected from among thienyl, fury...
|
|
WO/2003/084912A1 |
Benzoylcyclohexanedione derivatives of formula (I) and use thereof as herbicides are disclosed. In said general formula (I) R1a, R1b, R1c, R2, R3, R4 and R5 = various groups, X1 = a bridging atom, X2 = a hydrocarbon chain and X3 = a chal...
|
|
WO/2003/082280A1 |
Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5 and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds,...
|
|
WO/2003/079984A2 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2003/080545A2 |
Substituted phenylacetic acids, phenylethanols and related compounds are provided that are useful in treating or controlling a number of diseases associated with glucose metabolism, lipid metabolism and insulin secretion.
|
|
WO/2003/078392A2 |
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of th...
|
|
WO/2003/078433A1 |
A process for producing crystalline form I of cabergoline, which process comprises the preparation of Form V using heptane as precipitation solvent, and its exclusive conversion into crystalline Form I of cabergoline. The present crystal...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/077828A2 |
The present invention relates to novel florfenicol compounds having the chemical structure (I) wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without lim...
|
|
WO2003029199A9 |
Novel benzene derivatives represented by the general formula (||), which exhibit vanilloid receptor agonism and are useful as preventive and therapeutic drugs for pollakisuria and urinary incontinence, analgesic, or the like: (||) wherei...
|
|
WO/2003/078408A1 |
Parecoxib sodium is provided in a crystalline form that is substantially anhydrous and substantially nonsolvated. Various such anhydrous, nonsolvated crystal forms have been identified, including Forms A, B and E as described herein. Als...
|
|
WO/2003/076422A1 |
This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing th...
|
|
WO2002062750A9 |
There are disclosed compounds of the formula (I) a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disc...
|
|
WO/2003/076419A1 |
It is intended to provide isoxazole derivatives represented by the following general formula (1) and a process for producing the same: (1) wherein R1 represents hydrogen, C1-20 hydrocarbyl or -C(=O)OR1a (wherein OR1a represents C1-10 alk...
|
|
WO/2003/075857A2 |
Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.
|
|
WO/2003/075836A2 |
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
WO/2003/074476A1 |
An arylamidine derivative represented by the general formula (1) (wherein X means optionally substituted lower alkylene or alkenylene; G1 means oxygen, sulfur, or imino; G2 means carbon or nitrogen; Ra means at least one member selected ...
|
|
WO/2003/074501A1 |
An agri- and horticultural fungicide comprising a substituted isoxazole alkylamine derivative of the general formula (I) as an effective ingredient exhibits a satisfactory plant disease control activity without cross with known drug tole...
|
|
WO/2003/074495A1 |
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseas...
|
|
WO/2003/072535A2 |
This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2003/072552A1 |
The present invention relates to a process of preparing benzisoxazole methane sulfonic acid-chloride (BOS-CI) as an zonisamide intermediate via chlorination of benzisoxazole methane sulfonate. The present invention also disloses a proces...
|
|
WO/2003/072553A1 |
Compounds of formula B-C-A-CO-NH-R1, wherein A is structure i, ii or iii: formulae (I), (II), (III). C is optionally substituted aryl or heteroaryl, and B is a specified cyclic moiety, or C and B together are a heterobicyclic moiety, are...
|
|
WO/2003/072104A1 |
Disclosed are processed for preparing novel carbamate intermediates of paroxetine comprising delakylating N-alkylparoxetine by reaction thereof with a haloalkyl ester of a haloformic acid, in a suitable organic solvent. Also disclosed ar...
|
|
WO/2003/070690A2 |
The invention relates to compounds of formula (I): where R1 = an aryl, heteroaryl or alkyl group, optionally substituted with a group of formula -(CO)-CR6R7NR8R9, where R6, R7, R8 and R9 are as defined in the description, R2 = H or optio...
|
